HALO - Halozyme Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Annual

Cash Flow

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Cash flows from operating activities
Net Income
-39,969
-80,330
62,971
-103,023
-32,231
Depreciation & amortization
3,616
2,388
2,161
2,410
1,677
Deferred income taxes
-
-
-
-
-
Stock based compensation
36,559
35,696
30,670
25,585
20,838
Change in working capital
-41,130
-5,866
20,688
16,978
-29,497
Accounts receivable
-13,088
11,613
-6,453
16,730
-23,261
Inventory
-17,767
-17,480
9,477
-5,134
-3,083
Accounts Payable
-
-
-
-
-
Other working capital
-54,808
-54,163
132,703
-53,520
-39,443
Other non-cash items
-4,288
1,697
17,820
7,107
1,243
Net cash provided by operating activites
-48,336
-49,500
134,053
-50,383
-37,083
Cash flows from investing activities
Investments in property, plant and equipment
-6,472
-4,663
-1,350
-3,137
-2,360
Acquisitions, net
-
-
-
-
-
Purchases of investments
-280,051
-311,112
-398,187
-155,412
-71,482
Sales/Maturities of investments
414,601
318,268
235,805
81,783
79,730
Other investing activites
-
-
-
0
0
Net cash used for investing activites
128,078
2,493
-163,732
-76,766
5,888
Cash flows from financing activities
Debt repayment
-83,715
-77,516
-15,995
-54,250
-
Common stock issued
-
0
134,874
0
0
Common stock repurchased
-
-
-
-
-
Dividends Paid
-
-
-
-
-
Other financing activites
-
-
-
0
0
Net cash used privided by (used for) financing activities
-75,559
-63,797
131,655
150,621
13,098
Net change in cash
4,183
-110,804
101,976
23,472
-18,097
Cash at beginning of period
55,519
169,240
67,264
43,292
61,389
Cash at end of period
59,702
58,436
169,240
66,764
43,292
Free Cash Flow
Operating Cash Flow
-48,336
-49,500
134,053
-50,383
-37,083
Capital Expenditure
-6,472
-4,663
-1,350
-3,137
-2,360
Free Cash Flow
-54,808
-54,163
132,703
-53,520
-39,443